Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp.TNXP · Entity 6169 | Director · Chief Executive Officer | August 27, 2026 | August 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tonix Pharmaceuticals Holding Corp.
Report date August 27, 2026 · Filed August 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectBy IRA Account | 11,005 |
Reported balance
After 2026-08-27 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-27 · Purchase · Acquired 2,000 · Balance 11,005 F1: Reporting person may be deemed a control person of this entity. |
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 20,001 |
Reported balance
Holding disclosure · report date 2026-08-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 20,001 |
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectLederman & Co. | 1 |
Reported balance
Holding disclosure · report date 2026-08-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1 F1: Reporting person may be deemed a control person of this entity. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting person may be deemed a control person of this entity.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 27, 2026 Filed Aug 31, 2026 12:00 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 2,000 | $13.79 | $27,580.00 |
DisclosureSEC source: 0001493152-26-040736 · ownership.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By IRA Account Disclosed balance after: 11,005 F1 · ownership.nature: Reporting person may be deemed a control person of this entity. Read SEC document |
| June 09, 2026 Filed Jun 9, 2026 21:30 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 5,000 | $11.79 | $58,950.00 |
DisclosureSEC source: 0001493152-26-027986 · ownership.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,005 F1 · price: Represents the weighted average purchase price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $11.735 to $11.883 per share. The Reporting Person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 13:31 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 5,000 | $12.62 | $63,100.00 |
DisclosureSEC source: 0001999371-26-007447 · ownership.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By IRA Account Disclosed balance after: 20,001 F1 · price: Represents the weighted average purchase price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $12.5699 to $12.625 per share. The Reporting Persons undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F2 · ownership.nature: Reporting person may be deemed a control person of this entity. Read SEC document |
| March 18, 2026 Filed Mar 18, 2026 21:03 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 15,000 | $14.89 | $223,350.00 |
DisclosureSEC source: 0001999371-26-006235 · form4-lederman_031826.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By IRA Account Disclosed balance after: 15,001 F1 · ownership.nature: Reporting person may be deemed a control person of this entity. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 12:01 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 134,503 | $0.00 Strike: $17.86 | $0.00 |
DisclosureSEC source: 0001999371-26-004385 · lederman-form4_022626.xml · derivative · entry 2 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,503 Underlying: Common Stock · 134,503 shares Expires 2036-02-24 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 12:01 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 134,504 | $0.00 Strike: $14.29 | $0.00 |
DisclosureSEC source: 0001999371-26-004385 · lederman-form4_022626.xml · derivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,504 Underlying: Common Stock · 134,504 shares Expires 2036-02-24 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. Read SEC document |
| May 15, 2025 Filed May 15, 2025 21:08 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 4,000 | $21.55 | $86,200.00 |
DisclosureSEC source: 0001999371-25-006261 · lederman-ownership.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,005 Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:48 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 123,958 | $0.00 Strike: $10.06 | $0.00 |
DisclosureSEC source: 0001839882-25-011952 · lederman-form4_022725.xml · derivative · entry 8 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,958 Underlying: Common Stock · 123,958 shares Expires 2035-02-25 F4 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F3 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:48 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 123,958 | $0.00 Strike: $8.05 | $0.00 |
DisclosureSEC source: 0001839882-25-011952 · lederman-form4_022725.xml · derivative · entry 7 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,958 Underlying: Common Stock · 123,958 shares Expires 2035-02-25 F4 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F3 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 05, 2025 Filed Feb 27, 2025 23:48 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | OtherCommon Stock, $0.001 par value | 1 | $0.15 | $0.15 |
DisclosureSEC source: 0001839882-25-011952 · lederman-form4_022725.xml · nonDerivative · entry 6 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 0 F2 · kind: Involuntary sale of fractional share following a reverse stock split of the Issuer's common stock. Read SEC document |
| February 05, 2025 Filed Feb 27, 2025 23:48 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | OtherCommon Stock, $0.001 par value | 0.22 | $3.30 | $0.73 |
DisclosureSEC source: 0001839882-25-011952 · lederman-form4_022725.xml · nonDerivative · entry 5 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By IRA Account Disclosed balance after: 1 F2 · kind: Involuntary sale of fractional share following a reverse stock split of the Issuer's common stock. Read SEC document |
| February 05, 2025 Filed Feb 27, 2025 23:48 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | OtherCommon Stock, $0.001 par value | 5.18 | $3.38 | $17.51 |
DisclosureSEC source: 0001839882-25-011952 · lederman-form4_022725.xml · nonDerivative · entry 4 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5 F2 · kind: Involuntary sale of fractional share following a reverse stock split of the Issuer's common stock. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:08 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 1,309,911 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001999371-24-002952 · lederman-form4_022724.xml · derivative · entry 3 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,309,911 Underlying: Common Stock · 1,309,911 shares Expires 2034-02-27 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:08 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 1,903,680 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001999371-24-002952 · lederman-form4_022724.xml · derivative · entry 2 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,903,680 Underlying: Common Stock · 1,903,680 shares Expires 2034-02-27 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:08 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 235,320 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001999371-24-002952 · lederman-form4_022724.xml · derivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,320 Underlying: Common Stock · 235,320 shares Expires 2034-02-27 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 27, 2024 Filed Mar 6, 2024 22:01 UTC Amendment | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 1,309,911 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001999371-24-003168 · ownership.xml · derivative · entry 3 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,309,911 Underlying: Common Stock · 1,309,911 shares Expires 2034-02-27 F3 · derivative.exercise_price: The amendment corrects the Conversion or Exercise Price of from $0.0368 to $0.368. F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. Read SEC document |
| February 27, 2024 Filed Mar 6, 2024 22:01 UTC Amendment | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 1,903,680 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001999371-24-003168 · ownership.xml · derivative · entry 2 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,903,680 Underlying: Common Stock · 1,903,680 shares Expires 2034-02-27 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 27, 2024 Filed Mar 6, 2024 22:01 UTC Amendment | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 235,320 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001999371-24-003168 · ownership.xml · derivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,320 Underlying: Common Stock · 235,320 shares Expires 2034-02-27 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 23, 2023 Filed Feb 24, 2023 23:34 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 700,000 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001839882-23-004701 · lederman-form4_022322.xml · derivative · entry 2 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2033-02-23 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 23, 2023 Filed Feb 24, 2023 23:34 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 700,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001839882-23-004701 · lederman-form4_022322.xml · derivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2033-02-23 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| June 29, 2022 Filed Jul 1, 2022 20:05 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 20,000 | $1.71 | $34,200.00 |
DisclosureSEC source: 0001387131-22-007441 · lederman-form4.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Account Disclosed balance after: 24,235 F1 · balance_after: Shares reported reflect a 1-for-32 reverse stock split effective May 17, 2022. Read SEC document |
| March 25, 2022 Filed Mar 28, 2022 12:00 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 100,000 | $0.25 | $24,500.00 |
DisclosureSEC source: 0001387131-22-003991 · lederman-form4_032522.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,177 Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 22:17 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 5,000,000 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001387131-22-002105 · lederman-form4_021522.xml · derivative · entry 4 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000,000 Underlying: Common Stock · 5,000,000 shares Expires 2032-02-15 F3 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F2 · derivative.exercise_date: 10% of the option vests on the first anniversary of issuance, 10% on the second anniversary of issuance, 40% on the third anniversary of issuance, and 40% on the fourth anniversary of issuance. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 22:17 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 5,000,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001387131-22-002105 · lederman-form4_021522.xml · derivative · entry 3 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000,000 Underlying: Common Stock · 5,000,000 shares Expires 2032-02-15 F3 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F2 · derivative.exercise_date: 10% of the option vests on the first anniversary of issuance, 10% on the second anniversary of issuance, 40% on the third anniversary of issuance, and 40% on the fourth anniversary of issuance. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 22:17 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 5,000,000 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001387131-22-002105 · lederman-form4_021522.xml · derivative · entry 2 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000,000 Underlying: Common Stock · 5,000,000 shares Expires 2032-02-15 F3 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F2 · derivative.exercise_date: 10% of the option vests on the first anniversary of issuance, 10% on the second anniversary of issuance, 40% on the third anniversary of issuance, and 40% on the fourth anniversary of issuance. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 22:17 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 5,000,000 | $0.00 Strike: $0.21 | $0.00 |
DisclosureSEC source: 0001387131-22-002105 · lederman-form4_021522.xml · derivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000,000 Underlying: Common Stock · 5,000,000 shares Expires 2032-02-15 F3 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| September 28, 2021 Filed Sep 28, 2021 21:04 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 12,000 | $0.61 | $7,320.00 |
DisclosureSEC source: 0001387131-21-009696 · lederman-form4_092821.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,177 Read SEC document |
| March 24, 2021 Filed Mar 25, 2021 11:00 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 16,733 | $1.32 | $22,087.56 |
DisclosureSEC source: 0001387131-21-003875 · ownership.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) plan Disclosed balance after: 135,000 Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:54 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 3,000,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001387131-21-002890 · ownership.xml · derivative · entry 2 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000,000 Underlying: Common Stock · 3,000,000 shares Expires 2031-02-23 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:54 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 3,000,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001387131-21-002890 · ownership.xml · derivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000,000 Underlying: Common Stock · 3,000,000 shares Expires 2031-02-23 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:01 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 35,000 | $0.68 | $23,800.00 |
DisclosureSEC source: 0001387131-21-000041 · lederman-form4_123020.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,267 F1 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.6801 to $0.6805, inclusive. The reporting person undertakes to provide to Tonix Pharmaceuticals Holding Corp., any security holder of Tonix Pharmaceuticals Holding Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 13:03 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 60,000 | $0.91 | $54,600.00 |
DisclosureSEC source: 0001387131-20-007592 · lederman-form4_0813020.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) plan Disclosed balance after: 83,267 Read SEC document |
| May 04, 2020 Filed May 6, 2020 22:22 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 2,000,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001387131-20-004481 · ownership.xml · derivative · entry 2 LEDERMAN SETH · CIK 0001563420 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2030-05-04 F2 · price: 2. The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| May 04, 2020 Filed May 6, 2020 22:22 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 2,000,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001387131-20-004481 · ownership.xml · derivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2030-05-04 F2 · price: 2. The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 21:22 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 120,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001387131-20-002253 · ownership.xml · derivative · entry 2 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2030-02-25 F2 · price: The option was granted pursuant to the Issuer's 2020 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 21:22 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 120,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001387131-20-002253 · ownership.xml · derivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2030-02-25 F2 · price: The option was granted pursuant to the Issuer's 2020 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 12:00 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 20,000 | $1.16 | $23,180.00 |
DisclosureSEC source: 0001387131-19-009327 · lederman-form4_120319.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) plan Disclosed balance after: 23,267 Read SEC document |
| May 06, 2019 Filed May 8, 2019 12:01 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 129,757 | $0.00 Strike: $2.56 | $0.00 |
DisclosureSEC source: 0001387131-19-003428 · ownership.xml · derivative · entry 2 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,757 Underlying: Common Stock · 129,757 shares Expires 2029-05-06 F2 · price: The option was granted pursuant to the Issuer's 2019 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| May 06, 2019 Filed May 8, 2019 12:01 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 129,758 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001387131-19-003428 · ownership.xml · derivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,758 Underlying: Common Stock · 129,758 shares Expires 2029-05-06 F2 · price: The option was granted pursuant to the Issuer's 2019 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| March 29, 2019 Filed Apr 1, 2019 12:22 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 5,000 | $2.49 | $12,440.00 |
DisclosureSEC source: 0001387131-19-002339 · lederman-form4_032919.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) Plan Disclosed balance after: 32,670 Read SEC document |
| March 26, 2019 Filed Mar 28, 2019 21:13 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 25,000 | $2.38 | $59,375.00 |
DisclosureSEC source: 0001387131-19-002230 · ownership.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) plan Disclosed balance after: 27,670 F1 · price: Weighted average purchase price. Actual purchase prices ranged from $2.335 to $2.40. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 22:29 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 23,265 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001387131-19-001528 · ownership.xml · derivative · entry 2 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,265 Underlying: Common Stock · 23,265 shares Expires 2029-02-25 F2 · price: The option was granted pursuant to the Issuer's 2018 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 22:29 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 23,265 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001387131-19-001528 · ownership.xml · derivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,265 Underlying: Common Stock · 23,265 shares Expires 2029-02-25 F2 · price: The option was granted pursuant to the Issuer's 2018 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| June 29, 2018 Filed Jul 2, 2018 20:30 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 500 | $4.64 | $2,320.00 |
DisclosureSEC source: 0001615774-18-006088 · s111175_form4.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,666 Read SEC document |
| June 28, 2018 Filed Jun 29, 2018 20:30 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 500 | $4.58 | $2,290.00 |
DisclosureSEC source: 0001615774-18-006006 · s111120_form4.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,166 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.57 to $4.59 per share, inclusive. The reporting person undertakes to provide to Tonix Pharmaceuticals Holding Corp. ("Tonix"), any security holder of Tonix, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| June 27, 2018 Filed Jun 28, 2018 20:30 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 500 | $4.55 | $2,275.00 |
DisclosureSEC source: 0001615774-18-005896 · s111090_form4.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,666 Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 20:06 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 2,000 | $4.37 | $8,740.00 |
DisclosureSEC source: 0001615774-18-005290 · s110815_form4.xml · nonDerivative · entry 2 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Lederman & Co., LLC Disclosed balance after: 20,463 F1 · ownership.nature: Reporting person may be deemed to be a control person of this entity. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 20:06 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 1,000 | $4.37 | $4,370.00 |
DisclosureSEC source: 0001615774-18-005290 · s110815_form4.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,166 Read SEC document |
| May 25, 2018 Filed May 30, 2018 20:05 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 4,000 | $3.17 | $12,680.00 |
DisclosureSEC source: 0001615774-18-004510 · s110480_form4.xml · nonDerivative · entry 1 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) plan Disclosed balance after: 26,700 Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 21:08 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 156,601 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001615774-18-001263 · s109082_form4.xml · derivative · entry 2 LEDERMAN SETH · CIK 0001563420 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,601 Underlying: Common Stock · 156,601 shares Expires 2028-02-12 F2 · price: The option was granted pursuant to the Issuer's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.